

42205



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

REINL et al.

Serial No.: 09/667,237

Filed: 22 September 2000

For: CREATION OF VARIABLE LENGTH
AND SEQUENCE LINKER REGIONS
FOR DUAL-DOMAIN OR
MULTI-DOMAIN MOLECULES.

Group Art Unit: 1639

Examiner: Epperson

RECEIVED
FEB 10 2003
TECH CENTER 1600/2900

#17998
2-20-03

REPLY TO NOTICE TO COMPLY

Box Sequence

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This is in reply to the Notice (mailed to the incorrect address), copy attached hereto.

A paper copy and CRF of the Sequence Listing, along with the requisite statement of identity of content were filed on 14 March 2002. A copy of the filing is enclosed, along with the stamped post card.


It will be seen that all of the sequences are represented in the Listing.

Thus, vacation of the Notice is in Order.

Finally, please note the Revocation and address changes filed previously.

Respectfully submitted,

Reg. No. 45,867


Dean H. Nakamura
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036
(202) 659-9076
Dated: 6 February 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
FEB 10 2003
TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/667,237	09/22/2000	Stephen J. Reinl	11209-16002

VENABLE
Post Office Box 34385
Washington, DC 20043-9998



CONFIRMATION NO. 1339

FORMALITIES LETTER

OC000000007155294

Date Mailed: 12/04/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).


For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART I - ATTORNEY/APPLICANT COPY



DOCKETED


CLIENT/MATTER # 11209-16002 ATTY 521
DUE DATE February 9, 2002 (Sequence Listing due)
FINAL DEADLINE August 7, 2002
DKTED BY Red/BV




Due Date 4 April 2002 Today's Date 14 March 2002 (4)
USSN/USP 09/667,237 RAB&G FILE NO. 42205 BY: DB/KC
In Re Reinl et al.
For Creation of Variable length and Sequence Link...

The following was received in the U.S. Patent & Trademark Office on the date stamped hereon:

- ☒ Check for \$ 200.00
- ☐ Specification _____ pgs. _____ claims
- ☐ Combined Decl., Petition & Power
- ☐ Assignment
- ☐ Drawings _____ Sheets ☐ Formal ☐ Informal
- ☐ Small Entity Statement
- ☐ Claim for Priority & ☐ Document
- ☐ Information Disclosure Statement
- ☐ Trademark Application & _____ Specimens
- ☐ Rule 53(b) Appln. ☐ Rule 53(d) Appln. (CPA)
- ☐ Amendment ☐ Response
- ☐ Notice of Appeal
- ☐ Brief ☐ Req. Oral Hearing
- ☐ Issue Fee Transmittal
- ☐ Trademark Renewal Application
- ☐ Decl. of Use ☐ 8 ☐ 15
- ☒ Petition to Extend 2 mos./days
- ☐ Completion of Application
- ☒ Sub of Sgs Listing
- ☒ Statement
- ☐ Due Date Not Related To Response



RECEIVED
FEB 10 2003
TECH CENTER 1600/2900



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

SZL
18696769191

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/667,237	09/22/2000	Stephen J. Reinl	18696-169197	1339

26694 7590 01/06/2003

VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP
P.O. BOX 34385
WASHINGTON, DC 20043-9998

EXAMINER

EPPERSON, JON D

ART UNIT

PAPER NUMBER

1639

DATE MAILED: 01/06/2003

PREVIOUSLY DOCKETED
File Transferred



Please find below and/or attached an Office communication concerning this application or proceeding.


~~DOCKETED~~
CLIENT/MATTER # _____ ATTY _____
DUE DATE _____
FINAL DEADLINE _____
DKTED BY _____

TECH CENTER 1600/2900

FEB 10 2003

RECEIVED





UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/667,237	08/09/2000	Reini, Stephen J.	18696-169197

EXAMINER	
Jon D. Epperson, Ph. D.	
ART UNIT	PAPER NUMBER
1639	16

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Notice To Comply: Sequence Rules (Bonafide)

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2) (e.g., see Gly₄Ser in claims 48 and 51; see also "(Gly₄Ser)₃" sequence on page 35, line 29; page 38, lines 5 and 20, etc). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in **ABANDONMENT** of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.


Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Any inquiry concerning this communication should be directed to Jon D. Epperson whose telephone number is (703) 308-2423. The Examiner can normally be reached on Monday through Friday from 9 am to 6 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Andrew Wang, can be reached at (703) 306-3217. The fax number for this group is (703) 305-3014. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703) 308-0196.

JON D. EPPERSON, Ph.D.
PATENT EXAMINER

BENNETT CELSA
PRIMARY EXAMINER



PATENT

42205

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

FEB 10 2003

RECEIVED

In re Application of:

Stephen J. REINL et al.

Serial No.: 09/667,237

Filed: 22 September 2000

For: CREATION OF VARIABLE LENGTH
AND SEQUENCE LINKER REGIONS
FOR DUAL-DOMAIN OR
MULTI-DOMAIN MOLECULES

Group Art Unit: 1645

Examiner: TBA

SUBMISSION OF SEQUENCE LISTING


BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, copy attached hereto, submitted herewith is a CRF of the Sequence Listing, a written copy of the Sequence Listing as well as the requisite Statement. The due date for response is 4 February 2002, attached hereto and incorporated by reference is the Petition for Extension of Time for two-month extension making the due date for response 04 April 2002.


Respectfully submitted



Daryl A. Basham
Reg. No. 45,869

Roylance, Abrams, Berdo
& Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036-2680
(202) 659-9076

Dated: 14 March 2002



42205

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

FEB 10 2003

RECEIVED

TECH CENTER 1600/2900

In re Application of:

Stephen J. REINL et al.

Serial No.: 09/667,237

Filed: 22 September 2000

For: CREATION OF VARIABLE LENGTH
AND SEQUENCE LINKER REGIONS
FOR DUAL-DOMAIN OR
MULTI-DOMAIN MOLECULES

Group Art Unit: 1645

Examiner: TBA

STATEMENT ACCOMPANYING REPLY UNDER 37 CFR 1.821(f) AND (g)


BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 CFR 1.821 (f) and (g), the undersigned hereby states that the information recorded in computer readable form is identical to the written sequence listing. However, SEQ ID NO:12 was found to have an inadvertent transcription error in that a "c" was not listed after the first "a" residue in the oligonucleotide sequence. Examination of the specification as filed demonstrates the correct sequence for SEQ ID NO:12; i.e., at page 39, Table 2, first cell under the title cell, "act". As such, the undersigned hereby further states that the information and submission herein does not include any prohibited new matter.

Respectfully submitted,


Daryl A. Basham
Reg. No. 45,869

Roylance, Abrams, Berdo
& Goodman, L.L.P.
1300 19th Street, N.W., Suite 600
Washington, D.C. 20036-2680
(202) 659-9076

Dated: 